Clinical trials: Plaque
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Late Onset Alzheimer Disease
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline.
- Trial name
- NCT01222351
- Testing
- BAY 94-9172 (Florbetaben)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- New York State Psychiatric Institute
Psoriasis
An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of ustekinumab (CNTO 1275) compared with placebo in participants with moderate to severe plaque type psoriasis.
- Trial name
- NCT00723528
- Testing
- Ustekinumab 45 mg (CP), Ustekinumab 90 mg (CP)
- Where
- 27 sites in Japan
- Volunteers
- 158 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.
- Trial name
- NCT02054481
- Testing
- BI 655066, Ustekinumab
- Where
- 32 sites in United States, Canada and 5 more
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
- Trial name
- NCT02387801
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Plaque Psoriasis Efficacy and Safety With Secukinumab
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c.
- Trial name
- OPTIMISE (NCT02409667)
- Testing
- Secukinumab
- Where
- 200 sites in Austria, Belgium and 22 more
- Volunteers
- 16,487 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis
The purpose of this study is to establish proof of efficacy for namilumab in moderate to severe plaque psoriasis, measured as Psoriasis Area and Severity Index (PASI)75 response rate at Week 12.
- Trial name
- NCT02129777
- Testing
- Namilumab
- Where
- 10 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Takeda
Dental Plaque
Development of Clinical Method to Triclosan Retention in Plaque Following Brushing
The objective is to develop a method to determine active ingredient uptake in oral care products.
- Trial name
- NCT00762853
- Testing
- Fluoride, Fluoride and triclosan
- Where
- Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Psoriasis Vulgaris
A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 90100 cutaneous spray ointment, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.
- Trial name
- NCT01347255
- Testing
- LEO90100 cutaneous spray, ointment, LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate, LEO 90100 cutaneous spray, ointment, vehicle
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis, Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
- Trial name
- CIMPASI-1 (NCT02326298)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 234 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Induced Gingivitis
Induced Gingivitis & Intra-oral Imaging
Using an experimental, non-invasive intra-oral imaging device, this study evaluates the effects on the gingival tissue when oral hygiene is stopped in a section of the mouth for two weeks and gingivitis develops.
- Trial name
- NCT03750955
- Testing
- Plaque induced gingivitis, Oral hygiene maintenance
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Washington
Plaque Psoriasis
Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.
- Trial name
- NCT05268016
- Testing
- ME3183
- Where
- 27 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Meiji Pharma USA Inc.
Psoriasis
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type…
- Trial name
- POLARIS (NCT02951533)
- Testing
- Guselkumab, Fumaric Acid Esters
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Janssen-Cilag G.m.b.H
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Dental Plaque
Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
The objective is to compare two commerical oral products for the treatment of gingivitis.
- Trial name
- NCT00762515
- Testing
- Fluoride, Triclosan
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Psoriasis, Psoriatic Plaque
Light Treatment Effectiveness (LITE) Study
To compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis
- Trial name
- LITE (NCT03726489)
- Testing
- Daavlin 7 series 3 panel narrow band phototherapy home units, narrow band phototherapy clinic units
- Where
- 38 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Pennsylvania
Dental Plaque Induced Gingivitis, Dental Plaque
A Comparative Study of Electric Toothbrushes for the Efficacy Plaque Removal and the Effect on Plaque Accumulation and Gingivitis.
It is well accepted that the greatest contributor to the health of the periodontium and dentition is regular and thorough dental plaque removal, typically by means of adequate toothbrushing.
- Trial name
- NCT03416985
- Testing
- Oral B Healthy Clean Manual Toothbrush, BURST Sonic Oral Care, Philipps Sonicare DiamondClean 300 Series
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE SURE (NCT03412747)
- Testing
- Bimekizumab, Adalimumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 478 people
- Sponsor
- UCB Biopharma SRL
Periodontal Diseases, Dental Plaque
Oral Health Literacy Tailored Communication
The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.
- Conditions
- Periodontal Diseases, Dental Plaque, Dental Calculus, Sialorrhea
- Trial name
- NCT01118143
- Testing
- Tailored oral health literacy instruction
- Where
- 2 sites in Norway
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- University of Tromso